source
- Amgen drops early-stage obesity drug candidate AMG-513Amgen announced it is discontinuing its early-stage obesity candidate AMG-513. The program was in Phase 1, but the company provided no details about the study or the reasons for the halt. A spokes…
- Experts debate extra regulation for low-risk digital wellness devicesTwo recent papers published in JAMA have highlighted concerns about low-risk digital health technologies that consumers use. Experts say that even though these tools are considered low-risk, they…